eMeasure Name | Colorectal Cancer Screening | eMeasure Id | c796ebcb-b03e-4ed7-99b2-b706561456ef |
Version number | 1 | eMeasure Set Id | da479703-3931-40a0-909f-936ef106b1f1 |
Available Date | No information | Measurement Period | January 1, 20xx through December 31, 20xx |
Measure Steward | National Committee for Quality Assurance | ||
Endorsed by | National Quality Forum | ||
Description | The percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer. | ||
Copyright | © National Committee for Quality Assurance. All Rights Reserved |
||
Measure scoring | Proportion | ||
Measure type | Process | ||
Stratification | None |
||
Risk Adjustment | None |
||
Data Aggregation | |||
Rationale | This measure assesses the percentage of patients in a specific age demographic who receive appropriate screening for colorectal cancer. Colorectal cancer is the third leading cause of cancer-related deaths in the United States for both men and women, and was expected to be the primary cause of 49,920 deaths in 2009. In 2009, there were 106,100 new cases of colon cancer and 40,870 new cases of rectal cancer. Screening decreases mortality rates by detecting cancerous formations in the early and most curable stage; as a result, the mortality rate has been dropping for more than 20 years because of early identification of polyps for removal prior to disease onset, as well as other colorectal cancers. Screening is also fiscally responsible, with studies showing cost-savings of $40,000 per life-year gained. This measure facilitates efforts toward early detection of colorectal cancer and acceleration of treatment upon diagnosis. |
||
Clinical Recommendation Statement | The United States Preventive Services Task Force : [1]The USPSTF recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75 years (A recommendation). [2]The USPSTF concludes that the evidence is insufficient to assess the benefits and harms of computed tomographic (CT) colonography and fecal DNA testing as screening modalities for colorectal cancer (I statement). The American Cancer Society, The American College of Radiology, and the U.S. Multi-Society Task Force on Colorectal Cancer: Tests that Detect Adenomatous Polyps and Cancer [1]Colonoscopy (every 10 yrs) [2]Flexible sigmoidoscopy (every 5 yrs) [3]fecal occult blood tests (fecal occult blood test (FOBT)) (A) [4]Double contrast barium enema (DCBE) (every 5 yrs) [5]Computed tomographic colonography (CTC) (every 5 years) Tests that Primarily Detect Cancer: [1]gfecal occult blood test (FOBT) with high sensitivity for cancer (annually) [2]FIT with high sensitivity for cancer (annually) [3]sDNA with high sensitivity for cancer (interval uncertain) Modalities not approved: [1]Single digital rectal examination fecal occult blood test (FOBT) has a poor sensitivity for CRC and should not be performed as a primary screening method (A) [2]Studies evaluating virtual colonoscopy and fecal DNA testing for CRC screening have yielded conflicting results and therefore cannot be recommended (A) |
||
Improvement notation | Higher score indicates better quality |
||
Measurement duration | 12 month(s) |
||
Reference | Screening for Colorectal Cancer, Topic Page. October 2008. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/uspstf/uspscolo.htm |
||
Reference | Levin, B. MD, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:00-00 |
||
Definition | Initial Patient Population(s): All patients 51 to 75 years of age during the measurement period |
||
Definition | Denominator(s): Patients in the initial population with an outpatient encounter either during the measurement period or the 12 months prior to the measurement period |
||
Definition | Denominator Exclusion(s): Patients with a diagnosis or past history of total colectomy. Patients with a diagnosis or past history of colorectal cancer |
||
Definition | Numerator(s): The number of patients who had one or more screenings for colorectal cancer. Appropriate screenings are defined by the following criteria: N1: Fecal occult blood test (FOBT) during the measurement period N2: Flexible sigmoidoscopy during the measurement period or the four years prior to the measurement period N3: Colonoscopy during the measurement period or the nine years prior to the measurement period |
||
Definition | Denominator Exception(s): N/A |
||
Guidance | |||
Supplemental Data Elements | Report "Patient Characteristic: Gender" using "Gender HL7 Value Set (2.16.840.1.113883.1.11.1)"; Report "Patient Characteristic: Race" using "Race CDC Value Set (2.16.840.1.114222.4.11.836)"; Report "Patient Characteristic: Ethnicity" using "Ethnicity CDC Value Set (2.16.840.1.114222.4.11.837)"; Report "Patient Characteristic: Payer" using "Payer Source of Payment Typology Value Set (2.16.840.1.113883.3.221.5)". |
Measure set | CLINICAL QUALITY MEASURE SET 2011-2012 |